Key facts
- Notable investors include IDG Capital, Zhongguancun Development Venture Capital Fund, Zhongguancun Development Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Mengmou Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Mengmou Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mengmou Biotechnology
Developer of new drugs designed to treat degenerative eye diseases. The company's drugs utilizes innovative stem cells and gene therapies to treat eye diseases and can be used to solve degenerative diseases including dry macular degeneration as well, enabling patients to attain new drugs and treatments for previously incurable eye diseases.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Mengmou Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mengmou Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mengmou Biotechnology in its N-PORT filings yet. We sweep new filings monthly.